Gilead Sciences
Tracked across 29 events · 3164 articles · First seen Mar 09, 2018 · Last active Aug 19, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Gilead Sciences is acquiring Tubulis for up to $5.0 billion, gaining its next-generation antibody-drug conjugate platform and pipeline, which will enhance Gilead's oncology capabilities.
Apr 07, 2026 · 6 articles
Regulatory
Impact: The approval of Hepcludex by the United States — Food and Drug Administration>>> expands Gilead Sciences>>>' liver disease portfolio and positions it as a primary player in the hepatitis D treatment market. This approval is a significant commercial advancement for Gilead Sciences>>>.
May 22, 2026 · 10 articles
Regulatory
Impact: Gilead was the defendant and primary beneficiary of the ruling, which dismissed negligence claims from 24,000 HIV patients. The decision protects its HIV drug franchise, which accounts for 70% of its revenue, and removes a potential liability.
Aug 03, 2026 · 6 articles
Regulatory
Impact: Gilead Sciences is among the pharmaceutical companies that agreed to lower drug prices for United States — Medicaid and cash payers as part of the deals with the Donald Trump administration.
Dec 19, 2025 · 7 articles
Business
Impact: Gilead Sciences is a pharmaceutical company that has been actively involved in acquisitions this year and is also facing patent expirations on some of its blockbuster drugs.
May 01, 2026 · 6 articles
Tech
Impact: Gilead Sciences developed Lenacapavir and has committed to granting a voluntary manufacturing license to a South African company, which will allow for cheaper generic versions of the drug.
Jun 09, 2026 · 8 articles
Tech
Impact: Manufactures remdesivir (Veklury). Positive study results may support increased use and sales in transplant populations.
Jul 28, 2026 · 6 articles
Tech
Impact: Gilead Sciences developed the antiviral remdesivir and experimental oral antiviral obeldesivir, both prioritized by the World Health Organization for treatment and prevention of the Bundibugyo strain of Ebola.
May 28, 2026 · 6 articles
Accidents
Impact: Gilead Sciences is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.
May 15, 2026 · 446 articles
International
Impact: Developed lenacapavir, a highly effective HIV prevention injectable; faces potential revenue impact from generic production in South Africa.
Jul 21, 2026 · 6 articles
Accidents
Impact: Supplying remdesivir for clinical trials; potential positive impact if treatment proves effective.
Mar 09, 2018 · 314 articles
Accidents
Impact: Developed obeldesivir, the antiviral being tested in the EBO-PEP trial.
Jul 06, 2026 · 410 articles
International
Impact: Facing pressure to expand access to lenacapavir; its pricing and licensing decisions are under scrutiny.
Jul 21, 2026 · 68 articles
Accidents
Impact: Gilead Sciences' antiviral drug remdesivir and experimental drug obeldesivir are being prioritized for clinical trials to treat or prevent the Bundibugyo ebolavirus, indicating its significant role in potential therapies.
May 18, 2026 · 505 articles
International
Impact: Gilead Sciences' experimental oral COVID antiviral drug, Obeldesivir, is being considered for use as a preventative treatment for Ebola contacts, under strict protocol.
May 21, 2026 · 627 articles
Regulatory
A securities class action lawsuit has been filed against iTonic Holdings Ltd. (formerly Pheton Holdings Ltd.), a microcap company listed on NASDAQ under ticker ITOC (previously PTHL). The lawsuit alleges that between September 5, 2024…
Impact: Gilead Sciences was mentioned in false rumors of an acquisition, which allegedly contributed to the manipulation scheme. The company denied any contact with iTonic.
Aug 04, 2026 · 91 articles
International
Impact: Gilead Sciences' antiviral remdesivir is mentioned as a potential treatment to be used at the quarantine facility, indicating its role in the medical response to Ebola.
May 26, 2026 · 213 articles
Regulatory
Impact: Gilead Sciences is one of the companies whose drug approvals are being bet on, but is not directly involved.
Jul 16, 2026 · 7 articles
Tech
Impact: Gilead collaborates with Nurix on an IRAK4 degrader, but this event does not directly affect that program.
Aug 04, 2026 · 6 articles
Business
Cocrystal Pharma, Inc., a clinical-stage biotechnology company developing antiviral therapeutics, announced the appointment of Carol Brosgart, MD to its Board of Directors, effective August 12, 2026. Dr. Brosgart brings decades of experience in antiviral therapy,…
Impact: Gilead Sciences is mentioned as Brosgart's former employer, where she contributed to antiviral drug development; no direct impact on Gilead.
Aug 17, 2026 · 6 articles
Business
Impact: Gilead has a separate collaboration with Nurix for an IRAK-4 degrader, but is not directly involved in this event.
Jul 21, 2026 · 6 articles
Business
On August 10, 2026, Novo Nordisk and Amazon — Amazon Web Services (AWS) announced a strategic partnership to accelerate drug discovery and modernize operations through agentic AI and cloud technologies. The agreement establishes AWS as…
Impact: Gilead Sciences is mentioned as an existing AWS customer, but this event does not directly impact it.
Aug 10, 2026 · 7 articles
Domestic
Impact: Gilead is mentioned in relation to Remdesivir, but it is not directly involved in the event. Its role is peripheral.
Jul 26, 2026 · 353 articles
40
Gilead Sciences subject of false rumorsiTonic Holdings Securities...
Mapp Biopharmaceutical
partner
↔
Gilead Sciences
Gilead Sciences is collaborating with Mapp Biopharmaceutical on clinical trials
Mapp Biopharmaceutical
partner
↔
Gilead Sciences
Mapp Biopharmaceutical is collaborating with Gilead Sciences on clinical trials
+ 60 more relationships
View on Dashboard
ERGEN INTELLIGENCE
Track Gilead Sciences live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard